T1D is an autoimmune disease characterized by T cell-mediated destruction of 2 insulin-producing β-cells in the pancreatic islets of Langerhans, resulting in 3 hyperglycemia, with patients requiring lifelong insulin treatment. Many studies have 4
Introduction 14
The elucidation of the complex interactions between the gut microbiota, 15 metabolism, and the immune system may lead to groundbreaking changes as to how 16 specific diseases are prevented and treated. The gut microbiota refers to the community 17 of bacteria located within the intestine that have coevolved through millions of years with 18 the host. This symbiotic relationship is important for many host functions including 19 digestion, nutrient acquisition, and the development of the immune system 4 
. 20
The gut microbiota encodes trillions of genes, of which approximately 5-10 21 million are unique [5] [6] [7] . In total, there are ~150 times more genes than in the human 22 genome 6 . In healthy humans, the number of the bacteria increases exponentially from the 23 small intestine to the colon; thus, the colon is the main contributor to the total bacterial 24 population in the gut 8 . The main commensal bacterial phlya in the gut microbiota 25 include, Actinobacteria, Bacteroidetes, Firmicutes, Proteobacteria, and Verrucomicrobia 26 with the vast majority consisting of Bacteroidetes and Firmicutes. 27
The gut microbiota of each individual host is diverse and unique 9 . For 28 maintenance of good health, there is a natural balance between the host and its microbial 29 community. However, dysbiosis, which is a disturbance in the balance between the host 30 and the microbial community, is associated with various chronic diseases, including 31 obesity, inflammatory bowel disease (IBD), type 1 diabetes (T1D) and type 2 diabetes 1 (T2D) 10 . 2
Recent evidence suggests the gut microbiota may begin colonization in utero as 3 bacteria have been detected in the intrauterine environment including the amniotic fluid 11 , 4 placenta 12 , meconium 13 , and the umbilical cord 14 . While the majority of these studies 5 utilize 16S rRNA sequencing or PCR, in a small number the investigators have grown 6 bacteria by culturing the amniotic fluid 11 or the umbilical cord 14 samples in different 7 bacterial culture conditions. In addition, the development of the gut microbiota can be 8 influenced by the delivery mode. Infants delivered by Caesarean section (C-section) 9
exhibit less bacterial diversity up to 2 years after birth compared with those delivered 10 vaginally 15 . C-section deliveries have also been associated with an increased risk of 11 obesity 16 or T1D 17 later in life, which may be linked to the fact that the gut microbiota 12 continue to develop into adulthood 18 . This potentially provides a greater window of 13 opportunity for therapeutic modulation of the gut microbiota. 14 There are many ways that the gut microbiota can be modified, including the 15 environments we live in (e.g. rural or urban), diet and food supplements (probiotics), the 16 use of antibiotics or other medications during illness. Other factors, such as age and 17 gender, can also modify the microbial composition over time. For example, the healthy 18 pediatric gut microbiota exhibit significant compositional and functional differences from 19 those of adults 18 . It has been shown that children had increased abundances of 20 Bifidobacterium, Faecalibacterium, and Lachnospiraceae compared with adults, while 21 adults had increased abundance of Bacteroides 4 . Currently, it is not clear what 22 constitutes a "healthy" gut microbial composition; however, the microbiota are 23 indispensible for the digestion of nutrients 19 , development of mucosal immunity 20 , and 24 supporting gut-brain communication 21 . Furthermore, a loss of diversity in the gut 25 microbiota or alterations in microbial functions have been associated with risk of 26 developing chronic diseases including T1D and other autoimmune or inflammatory 27 disorders. Therefore, developing or retaining a "healthy" microbiota is important. 28
T1D is an autoimmune disease characterized by T cell-mediated destruction of 29 insulin-producing β-cells in the pancreatic islets of Langerhans, resulting in 30 hyperglycemia, with patients requiring lifelong insulin treatment. Many studies have 31
shown that genetics alone are not sufficient for the increase in T1D incidence and thus 1 other factors have been suggested to modify the disease risk. T1D incidence has sharply 2 increased in the developed world, especially amongst youth 1 . In Europe, T1D incidence 3 is increasing at an annual rate of 3-4% 2 . Increasing evidence shows that gut microbiota, 4
as one of the environmental factors influencing diabetes development, play an important 5 role in development of T1D 3 . Here, we summarize the current knowledge about the 6 relationship between the microbiota and T1D. We also discuss the possibility of T1D 7 prevention by changing the composition of gut microbiota. 8 9
Animal Models of T1D 10
To gain the best knowledge of the mechanism(s) of a disease development, the 11 ideal studies are in vivo investigations. For ethical reasons, there are considerable 12 limitations to in vivo studies in humans. However, animal models of human diseases 13 provide an alternative system to investigate the mechanism behind the immune response 14 within the pancreas, in the case of T1D, or the bacteria in the gut, in vivo, to answer 15 questions that we cannot do in humans. Utilizing bench to bedside and bedside to bench 16 approaches can further expand our understanding and help us to achieve the ultimate goal 17 of preventing T1D development or to develop a cure. 18
There are two widely used rodent models for human T1D research -the non-19 obese diabetic (NOD) mouse 22 and the bio-breeding (BB) rat 23 . Both the NOD mouse 20 and the BB rat develop spontaneous T1D, similar to humans. NOD mice usually develop 21 T1D after 10 weeks of age 24 , while BB rats develop T1D from 7 to 14 weeks 25 . In 22 affected humans, the age of onset of T1D typically ranges from 6 months to late 23 adolescence. The NOD mouse and the BB rat also carry the T1D susceptibility major 24 histocompatibility complex (MHC) class II genes, similar to the human T1D 25 susceptibility MHCII alleles. The NOD mouse recapitulates many features of human 26 T1D, especially those T1D susceptibility genes 26 . However, the pathogenesis of T1D in 27 both humans and animal models is not solely determined by genetics; the disease onset is 28 influenced by a combination of genetic and environmental factors. Pathologically, 29
humans 27 , the BB rat 28 and NOD mice 29 display infiltration of lymphocytes in the 30 pancreas, namely, insulitis. The immune cells that are involved in the destruction of 31 insulin-producing beta cells in humans, are similar to those cells present in NOD mice 1 and BB rats during diabetes development. These cells are mainly autoreactive T cells as 2 T1D is a T cell-mediated disease. Furthermore, the autoantigens that the T cell 3 recognizes in human T1D are also present in the NOD mouse 30 . In humans, a gender bias 4 emerges after puberty with a small increase in the number of affected males 31 , while the 5 majority of diabetic NOD mice are females 22 . However, there is no gender bias in T1D 6 development in BB rats 23 . 7
Unlike human studies, studies using animal models can be better controlled in 8 order to minimize variables and assess the effect of different environmental factors, such 9
as diet, mode of birth delivery and usage of medication, on the gut microbiota and the 10 development of T1D. Therefore, studies using animal models provide an extremely 11 valuable and unique tool for gaining more insightful knowledge about the disease. In 12 addition, humans 32 and rodents 33, 34 with T1D have been shown to exhibit similar 13 gastroenterological abnormalities, including increased intestinal permeability, altered 14 microvilli, leaky tight junctions, and altered gut microbiota [35] [36] [37] . Similar to humans, 15
Bacteroidetes and Firmicutes are also the dominant phyla in relation to the composition 16 of gut microbiota. However, there are also major differences as 85% of the bacterial 17 genera found in mice are absent in humans 38 . Moreover, a disadvantage of well-18 controlled studies using in-bred animal models may be a lack of direct translation to 19 humans, who are extremely heterogeneous. 20
21

Gut Microbiota and T1D 22 23
Hygiene Hypothesis 24
The concept of the gut microbiota as a major environmental factor influencing 25 T1D supports the rising incidence rates in developed countries. The hygiene hypothesis 26 originally was coined in relation to observations of respiratory problems, hygiene and 27 household size 39 . A modification of this may help to explain the increased T1D 28 incidence as a result of reduced diversity in the microbiota. The sharp increase in T1D 29
incidence dates back to the mid 20 th century where children were raised in environments 30 with increased levels of sanitation and thus have less exposure to bacteria and parasites. 31
The hygiene hypothesis has been tested in NOD mice, as the cleaner the living 1 conditions, the higher the incidence of diabetes found in NOD mice 40 . Moreover, studies 2 have found that infection of NOD mice early in life with a number of different bacteria 3 can prevent T1D 41, 42 . Human epidemiological studies showed that the incidence of T1D 4 and allergies is much lower in developing countries where the living standard is low but 5 the rate of bacterial or parasite infection is high 43 . Links found between gut microbiota 6 and T1D, discussed in this review, have prompted questions on how the gut microbiota 7
can be modulated in order to alter T1D development. Both the gut microbiota composition and the immune system co-evolve and 11 develop together over time, and young children have reduced microbial diversity and a 12 less mature immune system compared to adults 18, 44 . Therefore, it is important to 13 understand how the gut microbiota interacts with the immune system and further, how 14 these interactions alter susceptibility to T1D. Roesch and colleagues found that bacteria 15 of the Bacteroides genus were more common in diabetes-prone BB rats (BB-DP) than 16 they were in diabetes-resistant BB rats (BB-DR) 45 . However, the abundance of bacteria 17 belonging to the Lactobacillus and Bifidobacterium genera was higher in BB-DR rats 18 than in BB-DP rats 45 . Altered microbiota were also found between the NOD mouse and 19 non-obese diabetes resistant (NOR) mouse 46 . According to Daft and colleagues, the 20 NOD mouse has a lower Firmicutes:Bacteroidetes ratio as well as a lower abundance of 21
Prevotella compared to the NOR mouse 46 . This profile is also seen in children with T1D 22 compared to age-matched healthy children 37 . Long-term changes in the gut microbiota of 23 NOD or NOR mice can be accomplished by cross-fostering, whereby NOD mice are 24 nursed by NOR mothers and vice versa 46 . Cross-fostering of NOD mice results in both 25 the loss of some diabetogenic bacteria and the gain of bacteria associated with diabetes 26 protection. Further, NOD mice fostered by NOR mothers had a decreased incidence of 27 T1D 46 . 28
Gut microbiota can modulate T1D susceptibility associated with known T1D 29 susceptibility loci. Genetic susceptibility at the MHC loci is the most important risk 30 factor for T1D development in both NOD mice and humans. NOD mice express the gene 31 encoding MHC class II IA g7 , which is a homolog of human HLA-DQ8 47-49 . NOD mice 1 do not express IE, another MHC class II gene, a homolog of human HLA-DR 48, 49 . 2 Expression of IE, or expression of IA b , the MHC class II locus for C57BL/6 mice, instead 3 of IA g7 , is associated with protection from disease in NOD mice 50, 51 . Interestingly, a 4 recent study by Silverman et al. suggested the mechanism of disease protection is 5 mediated by gut microbiota in IE-expressing NOD mice 52 . The authors showed that 6 expression of the IE transgene results in the compositional changes in gut microbiota 7 which contributes to T1D protection. To prove that the disease protection was indeed 8 mediated by the gut microbiota, the authors treated the IE transgenic NOD mice with 9 different antibiotics. Administration of vancomycin or metronidazole, but not neomycin 10 or ampicillin, in the drinking water, disturbed the gut microbiota sufficiently to induce 11 insulitis in the normally insulitis-free IE transgenic NOD mice 52 . However, although the 12 presence of IA b in NOD mice was also able to alter the gut microbiota composition, the 13 effect on diabetes development was minimal 53 . Expression of other T1D protective 14 genetic loci Idd3 and/or Idd5 from C57BL/6 mice in NOD mice 54, 55 did not lead to 15 changes in gut microbiota but enhanced IL-2 production and Treg function. Mullaney 16 and co-authors further assessed the microbiota from healthy humans carrying the Idd3/5 17 protective alleles and found similar gut microbiota composition to NOD mice expressing 18 the same alleles 53 . These studies not only support the importance of the NOD mouse 19 model of human T1D, but also reveal the importance of the genetic susceptibility loci in 20 T1D, which modulate the interactions of immune cells and gut microbiota. 21
Alterations in the gut microbiota have also been observed in humans with T1D. 22
A study by Giongo and colleagues analyzed bacteria in fecal samples of infants and 23 young children and discovered that children who developed T1D had higher proportions 24 of bacteria from the Firmicutes phylum and lower proportions of bacteria in the 25
Bacteroidetes phylum than age-matched healthy controls at 4-8 months of age 37 . 26 However, by the age of 2, children who had developed T1D had a higher proportion of 27
Bacteroidetes and a lower proportion of Firmicutes relative to healthy controls 56 . Rather 28 than using stool samples, one study compared the duodenal gut microbiota of patients 29 with T1D, or those with celiac disease (CD) and with that of the healthy control 30 subjects 32 (due to proximity of the duodenum and close relationship to the pancreas). 31 Some patients with T1D in the study had a gastroduodenal endoscopy and biopsy for CD 1 diagnostic purposes. However, the authors found a distinctive inflammatory profile in 2 the patients with T1D 32 . Patients with T1D showed overexpression of ten inflammation-3 associated genes in the biopsies, including chemokines and TNFα, compared to both 4 healthy controls and CD patients 32 . Further, only patients with T1D exhibited an 5
increased Firmicutes and Firmicutes/Bacteroidetes ratio but reduced proportion of 6
Proteobacteria compared to either patients with CD or healthy controls 32 . 7
In addition, some studies have investigated the gut microbiota in individuals who 8 are positive for islet autoantibodies and those who are not. In a US-based study, the gut 9 microbiota composition was found to be different between seropositive individuals and 10 their seronegative first-degree relatives (FDRs) with an increased abundance of 11 Catenibacterium, Prevotellaceae and RC9 gut group bacteria in the former 57 . 12
Interestingly, the authors also found that the overall composition of gut microbiota in 13 autoantibody-positive individuals and seronegative FDRs were similar but different from 14 those recent-onset T1D patients and unrelated healthy controls 57 . It is not clear if the 15 FDRs were living in the same or a similar environment; however, this suggests some 16 genetic influence in the composition of gut microbiota and changes in the gut microbiota 17 prior to and/or soon after T1D development. In a European study, Endesfelder and 18 coauthors also compared the compostion of gut microbiota between seropositive or 19 seronegative individuals who have an FDR with T1D 58 . Their results did not reveal any 20 differences between autoantibody-positive and -negative individuals in microbiota 21 diversity and composition, as well as single-genus abundance 58 . However, the authors 22
found substantial changes in microbial interaction networks, especially in young children 23 who later developed autoantibodies 58 . In another study, the microbiota composition and 24 alpha diversity in European children, who had seroconverted and later developed 25 diabetes, was different to those who did not seroconvert 56 . In addition, the children who 26 seroconverted but had not developed diabetes by 3 years of age, had a microbiota 27 composition and alpha diversity more similar to non-seroconverters. Together, the data 28 confirmed microbial changes prior to and post-diabetes development. While most studies 29 have focused on 16S rRNA sequencing of the microbiota, Pinto and colleagues 30 investigated the microbial proteome, i.e. the proteins expressed by microbiota isolated 31 from stool samples of healthy children and children with T1D 59 . The authors found that 1 children with T1D had a higher abundance of proteins from Clostridia and Bacteroidetes, 2 while healthy children had a higher proportion of proteins from Bifidobacterium. 3
Although many studies provide evidence of altered gut microbiota in individuals with 4 T1D compared to healthy control subjects, few have shown a causal link between the 5 altered gut microbiota and the disease. However, it is important to note that some of the 6 human studies had very small group sizes, with as few as 3-4 individuals/group 37, 59 . 7 Thus, larger studies are needed. However, the data from the current human studies 8
suggest that the altered microbiota and their interactions with the immune system are 9
likely to contribute to T1D susceptibility. Therefore, it is important to do functional 10 studies in vivo and animal models can provide the perfect tools for this purpose. pathway, inducing proinflammatory cytokines that enable the innate immune system to 27 quickly eradicate potential microbial threats. 28
There are two major TLR signaling pathways mediated by different adaptor 29 proteins, the Myeloid differentiation primary response gene 88 (MyD88) and the Tir-30 domain-containing adaptor-inducing interferon β protein (TRIF). TLR3, a receptor for 31 double stranded RNA, relies solely on TRIF signaling, while TLR4, a receptor for LPS, 1 can signal through both MyD88 and TRIF; all the other TLRs rely on MyD88 63-65 . 2 Antigen presenting cells (APCs) express many TLRs and play an important role in 3 linking gut microbiota and the host immune system 66 . TLR signaling is essential because 4 it enables optimal antigen presentation by inducing APC maturation and costimulation, as 5 well as the release of cytokines 61, 65, 67-69 . 6
TLR interactions with the gut microbiota have been found to be important in 7
contributing to T1D susceptibility. MyD88-deficient (MyD88 -/-) NOD mice are 8 completely protected from diabetes under normal, specific-pathogen free (SPF) 9 conditions, where gut microbiota are present 70 . However, diabetes was partially restored 10 in the MyD88 -/-NOD mice after antibiotic administration, suggestive of microbial 11 involvement in the protection of the mice. Interestingly, re-deriving the MyD88 -/-NOD 12 mice to germ-free (GF) conditions abolished the disease protection. Introduction of 13 commensal bacteria to the GF MyD88 -/-NOD mice markedly reduced diabetes 14 development. These results demonstrate that MyD88-dependent signaling is important 15 for T1D development, which can be modulated by gut microbiota. Burrows and 16 colleagues reported that diabetes susceptibility in TLR4 -/-NOD mice and protection in 17 TLR2 -/-NOD mice were also modulated by gut microbiota 71 . LPS recognition has 18 recently drawn more attention in the T1D research field. It is known that Finland has the 19 highest T1D prevalence worldwide, whereas the incidence of T1D in Russia Karelia, a 20 close neighbor of Finland, is six times lower 72 . In addition, there is a greatly reduced risk 21 of developing other autoimmune and allergic diseases in Russion Karelia 73, 74 . 22
Investigation of the microbiota composition in children living in the different regions 23 revealed that Finnish children had more Bacteroides species encoding more LPS 24 synthesis genes, when compared to Russian infants 3 . Furthermore, the LPS from the 25 Bacteroides species isolated from Finnish children was structurally and functionally 26 different from the LPS of E.coli, a Bacteroides species, found in Russian infants. When 27 the immune function of the two different LPS types in NOD mice was tested, the LPS 28
from Bacteroides isolate of the Finnish children was more immunostimulatory than the 29 LPS from the E.coli isolate from the Russian children. The finding suggests that altered 30 LPS recognition by TLR4 may be important in modulating susceptibility to T1D. 31
Interestingly, TLR3-deficiency on the NOD background had no impact on diabetes 1 development; however, viral infection models of diabetes development required TLR3 on 2 both the NOD background as well as other genetic backgrounds for diabetes to develop 75-3 79 . Furthermore, it was noted that enhanced costimulatory molecule expression in the 4 islets, using transgenic constructs directed by the rat insulin promoter, involved changes 5 to the gut microbiota and signaling through TLR3 and MyD88 pathways 79 . Our studies 6 also showed that TLR9-deficient NOD mice 80 and TRIF-deficient NOD mice 81 are 7 protected from T1D development. LPS is the ligand of TLR4 and TRIF is one of the two 8 downstream signaling pathways of TLR4. It is interesting that diabetes protection in 9
TRIF-deficient NOD mice is mediated by gut microbiota 81 . Taken together, most TLRs 10 are required for T1D development in NOD mice, while TLR4 signaling regulates the 11 development of T1D through gut microbiota and/or LPS. 12
13
NLRs 14
Another family of PRR is the nucleotide-binding oligomerization domain-like 15 receptors (NLRs). These NLRs recognize both PAMPs and damage-associated 16 molecular patterns (DAMPs; molecules produced by stressed cells to promote an 17 inflammatory response). One of the best-studied NLRs is the nucleotide-binding 18 oligomerization domain-containing protein 2 (Nod2). Mutations in this receptor mediate 19 susceptibility to inflammatory bowel disease in humans 82, 83 . We recently showed that 20
Nod2 also influences T1D development in NOD mice, mediated by altered gut 21 microbiota 84 . In this study, Nod2 -/-NOD mice were protected from T1D only when 22
housed with other Nod2 -/-NOD mice. If the Nod2 -/-NOD mice were housed with Nod2-23 sufficient wild-type NOD mice, the Nod2 -/-NOD mice developed a similar T1D incidence 24
to WT NOD mice. This provides important evidence that the environmental conditions 25 e.g. housing status can alter the interpretation of the disease phenotype in genetically 26 modified mouse strains in T1D studies. 27
The nucleotide-binding oligomerization domain, leucine-rich repeat and pyrin 28 domain-containing 3 (NLRP3) inflammasome is another protein involved in the detection 29 of pathogens by innate immune cells. We found reduced expression of chemokines and 30 chemokine receptors on both pancreatic islets and T cells in NLRP3 -/-NOD mice, which 31 protected the mice from developing T1D 85 . It is currently unknown whether this process 1 is modulated by the gut microbiota. The role of other NLR members in mediating T1D 2 susceptibility is also unknown. differentiate to antibody-secreting plasma cells. IgM is the first antibody that B cells 2 produce in response to pathogen invasion. However, IgM is usually low affinity and 3 hence the need for affinity maturation including class switching, i.e., Ig gene 4 rearrangements, to generate antibodies with high affinity, in order to more specifically 5 target the antigen and control pathogen invasion [104] [105] [106] strains of bacteria in the ASF also contribute to the Treg conversion. However, these 7 studies suggest that Treg induction and the mechanism behind it depend on the type of 8 bacteria. More recently, Nod2, a member of the NLR family, which recognizes the 9 bacterial component muramyl dipeptide (MDP) was also found to regulate human Treg 10 survival by preventing apoptosis induced by MDP stimulation; however, Tregs from 11 patients with IBD, who have the Nod2 gene mutation, were not protected from 12 apoptosis 152 . We have shown recently that Nod2-deficient NOD mice are protected from 13 T1D development, which was, at least in part, mediated by increased gut microbiota-14
induced Tregs in the pancreatic lymph nodes 84 . This data shows the microbiota and 15 immune recognition together shape the regulatory T cell response and may provide an 16 important target for therapy. 17
18
Metabolism and the gut microbiota 19
The intestinal microbiota utilize undigested food products as substrates for 20 fermentation resulting in the production of different metabolites. Short-chain fatty acids 21 (SCFAs), saturated fats, L-carnitine, and choline are examples of microbially-derived 22 metabolites. Therefore, the presence of these metabolites depends on the microbiota 23 composition. Studies have shown that the metabolites, especially SCFAs influence the 24 differentiation and function of immune cells; thus, they may play an important role in the 25 development of T1D. 26
Other metabolic components including sex hormones can affect the immune 27 system including the induction of autoimmunity. The female gender bias in T1D 28 development seen in the NOD mice has been shown to be consequent upon interactions 29 between sex hormones and gut microbiota 138, 153 . The gut microbiota in male NOD mice 30 influence the levels of testosterone, and higher levels of testosterone are associated with 31 the protection against T1D development 153 . Several human autoimmune disorders have a 1 strong gender bias, with a higher incidence in women. While human T1D in adulthood 2 has a small gender bias towards men, it is important to decipher the role(s) of hormones 3 and microbiota including microbial products in mediating susceptibility to autoimmune 4 diseases. The short chain fatty acid propionate is converted into glucose in the intestine, 20 resulting in decreased glucose production from the liver 161 . Propionate also acts as an 21 agonist of FFAR3, inducing the peripheral nervous system to alter host metabolism by 22 decreasing adiposity, body weight and glucose production in the liver, thus promoting 23 better glucose control 162 . In addition, SCFAs can regulate the expression of peptide YY 24
(an enteroendocrine hormone) that controls gut motility and transit rate, as well as SCFA 25 uptake and can promote anti-inflammatory properties, offering protection from induced 26 inflammatory diseases such as colitis, arthritis and asthma in mouse models 163, 164 . Thus, 27 increased production of SCFAs from dietary fiber supplements or the ingestion of 28 probiotics can inhibit pro-inflammatory cytokines and chemokines that could be used in 29 potential treatments for autoimmunity e.g. colitis. However, a balance would be 30 required, as SCFAs are an additional source of calories and can be associated with 1 obesity and metabolic syndrome 165 . 2
While less is known about the role of SCFAs in the development of T1D, a few 3 recent studies have suggested that SCFAs can modulate T1D susceptibility. One study 4
showed that feeding NOD mice with acetylated or butyrated high-amylose maize starch 5 diets increased their serum concentrations of acetate or butyrate and protected NOD mice 6 from developing diabetes 166 . Further, protection was enhanced if NOD mice were fed 7 with a combination of both acetylated and butyrated diets. Interestingly, NOD mice fed 8 with the high acetate diet had reduced frequencies and numbers of islet autoantigen-9 reactive T cells in the spleen and pancreatic lymph nodes (PLNs). However, the 10 protection in NOD mice fed with a high butyrate-containing diet was related to increased 11
Treg number with enhanced suppressive functions 166 . Another study demonstrated that 12 butyrate could influence the secretion of cathelicidin-related antimicrobial peptide antibiotic treatment can change the availability of metabolites, which in turn, alters the 19 risk of developing T1D 168, 169 . Therefore, these options may prove useful in developing 20 prevention therapies. However, the relationship between microbial metabolism and 21 human T1D is still not well understood, and more studies in this area are needed in the 22
future. 23
Diet and Type 1 Diabetes 24
Diet is well known to influence microbial composition and functions. In Burkina 25 Faso, Africa, where diets consist of an abundance of complex carbohydrates resulting in 26 higher microbial diversity, children produce greater amounts of SCFAs when compared 27 to children from Europe 170 . In contrast, GF mice colonized with human stool bacteria 28 from an individual with a Western-style diet had less microbial diversity and a worsened 29 ability to metabolize complex carbohydrates. However, those mice given the stool 30 bacteria from the individuals with an enriched microbiota-accessible carbohydrate diet 31 had increased microbial diversity and were able to metabolize complex carbohydrates 19, 1 171 . Interestingly, numerous studies have suggested that Prevotella:Bacteroides ratios are 2 related to the dietary intake of either complex carbohydrate diets or proteins and fats 3 respectively 170, 172 . Of note, when dietary fibers are almost completely fermented, the pH 4 of the large intestine increases, providing a reduction in butyrate-producing microbiota 5 but an increase in acetate-and proprionate-producing Bacteroides bacteria 173 . 6
A barley kernel-based bread diet was introduced to healthy subjects for 3 days in a recent 7 dietary intervention study 174 . The authors identified the improvement of glucose 8 metabolism to be associated with an increased abundance of Prevotella copri 174 . The 9
presence of Prevotella in these individuals had enhanced enzymatic activity related to 10 breaking down complex carbohydrates, which promotes the generation of a number of 11
SCFAs. The colonization of GF mice with microbiota from the study participants also 12 confirmed an increased abundance of Prevotella that was associated with improved 13 glucose metabolism. Furthermore, branched-chain fatty acid produced by the 14 fermentation of branched-chain amino acids correlated with insulin resistance in germ-15 free mice receiving stool bacteria from obese human individuals 175 . 16
Dietary influence on T1D has been examined both as a causative agent as well as 17 a preventative or modulating factor. Oral administration of nicotinamide, a vitamin B 18 group substance, to NOD mice prevented the development of diabetes 176 . Further, NOD 19 mice were completely protected from T1D development when administered nicotinamide 20 in combination with a diet consisting of an infant formula, where soy was the source of 21 protein 177 . Vitamin D, specifically the active form, 1,25 di-hyroxyvitamin D, has also 22 been shown to prevent from severe insulitis due to the increased Treg cell activity [178] [179] [180] . 23
Gluten, a component of wheat protein, has many antigenic properties, and has been 24 implicated in the pathogenesis of several autoimmune disease states (predominantly CD) 25 but it has also been implicated in T1D. It has been reported that CD can affect up to 26 ~10% of individuals with T1D due to the overlap in HLA-DR3/DQ2 genetic susceptibility 27 between the two diseases 181, 182 . Furthermore, tissue transglutaminase antibodies are 28 present in some T1D patients, who share susceptibility SNPs to CD in the CTLA4 29 gene 183 . Even in those individuals with T1D who were negative for the tissue 30 transglutaminase autoantibody in the serum, the antibody was still found in the 31 jejunum 184 . Interestingly, T1D patients have increased expression of duodenal 1 inflammatory chemokines and cytokines compared to CD patients and healthy controls 32 . 2
This was also associated with altered microbiota in those T1D patients. Gluten-free diets 3 have been shown to protect NOD mice from the development of T1D 185-187 . Two studies 4 have shown that gluten in the diet affected the quantity and composition of the gut 5 microbiota 185, 186 . Funda and colleagues also reported that while a gluten-free diet 6
prevented diabetes in NOD mice, a gluten-enriched diet also had a preventative 7 effect 187 . They hypothesized that gluten itself is not diabetogenic but can have an 8 immunomodulatory effect on a diabetes-susceptible host by altering the gut microbiota 9 which in turn regulates the immune system. Human studies investigating how diet may 10 influence T1D susceptibility are currently underway. The BABYDIET study is a 11 prospective primary prevention trial recruiting children "at risk" of developing diabetes, 12
who have a first-degree relative with T1D and carry a T1D-risk HLA genotype. Children 13
were randomly assigned to one of two groups whereby gluten was introduced in the diet 14 at 6 months or 1 year of age 188 . Data from the participants within the first 3 years of age 15 showed similar prevalence of islet autoimmunity regardless of when gluten was 16 introduced; however, these children will continue to be followed over time, to observe 17 generation of autoantibodies and other markers that are associated with the development 18 of both celiac and T1D autoimmunity. modify the susceptibility of T1D development. Table 1 summarizes different studies 30 conducted to assess the role of microbial modulation in the development of T1D in NOD 31 mice. We have shown that vancomycin, which predominantly targets Gram-positive 1 bacteria, promoted T1D development in NOD mice, whereas neomycin, which targets 2 Gram-negative bacteria, protected NOD mice from T1D development 189, 190 . 3
Interestingly, others have reported that life-long vancomycin usage protected NOD mice 4 from T1D development 191 . It is clear that not all antibiotics have the same impact on 5 T1D development. Some antibiotics can protect NOD mice from the development of 6 T1D 189-191 , while others promote the development of diabetes in NOD mice 168, 192, 193 . 7
Interestingly, we found that the treatment of combination of four different antibiotics 8 (ampicillin, vancomycin, metronidazole and neomycin, AVMN) had no effect on 9 diabetes development in NOD mice despite the fact that the AVMN treatment depleted 10 most, if not all, gut bacteria (Peng, et al., unpublished) . This highlights the observation 11 that the treatment protocol can also influence diabetes development. In the study 12
showing that vancomycin protected NOD mice, the mice were treated from birth to 28 13 days of age or from 8 weeks of age to termination 191 . However, in the studies showing 14 that vancomycin accelerated T1D development, NOD mice were treated from conception 15 to termination or from conception to 24 hours post-birth 190, 193 . The different treatment 16 protocols, including dose, duration and starting age for these antibiotic studies make it 17 difficult to compare the outcome of different studies directly. Moreover, the gender of 18 the mice used in the studies may also affect diabetes development. As discussed earlier, 19 sex hormones influence the gut microbiota and T1D susceptibility in the NOD mouse 138, 20 153 . While most studies have used female mice, some studies have been conducted in 21 both genders. Candon and co-authors found that long-term (from conception to the 22 progeny at 40 wks of age) treatment with vancomycin or a combination of streptomycin, 23 colistin and ampicillin (Strep-Col-Amp) significantly increased diabetes development in 24 male NOD mice but had no effect on female mice 193 . In another study, male NOD mice 25 receiving tylosin also exhibited increased diabetes development 168 . Interestingly, the 26 female NOD mice, also exhibited increased diabetes development in one animal facility 27 but this was not reproducible in a second animal facility. This raises an important point 28 that the resident gut microbiota and animal facility standards can influence the 29 experimental outcome. This also raises the issue of reproducibility of studies as small 30 microbial changes may influence the effectiveness of the antibiotic treatment. Clearly, 31 these studies are not possible in humans; however, epidemiological investigations into 1 antibiotic usage and T1D development in humans have not shown any evidence that 2 antibiotics administered to children have influenced the onset of T1D. Probiotics are microorganisms that may have health benefits by modifying the gut 8 microbiota and improve nutrient absorption, enhance immune regulation and protect the 9 host from infection and disease 194 . While many of the probiotics may not colonize their 10 hosts in the long-term, they do have important immunomodulatory effects in the short-11 term 195 . 12
Probiotics have been shown to protect NOD mice and BB rats from developing 13 T1D 196-199 . Lactobacillus casei, which is believed to be a probiotic strain, can protect 14 NOD mice from T1D development when administered in the diet from 4 weeks of age 196 . 15
This protection was associated with decreased splenic CD8 T cell number and increased 16 IL-10 and IL-2 cytokines with age. The probiotic VSL#3 is a mixture of bifidobacteria 17 (Streptococcus salivarius subsp. thermophilus) 197 . In a study, Calcinaro and colleagues 20 administered VSL#3 to NOD mice, three times per week from 4 to 32 weeks of age and 21 this protocol led to significant protection from T1D development in treated NOD mice 22 compared to non-treated controls (21% vs 81% respectively). VSL#3 administration 23 decreased expression of IL-1β and increased expression of indoleamine 2,3-dioxygenase 24 and IL-33, both of which have tolerogenic properties 199 . However, in another study, 25 VSL#3 was administered via the drinking water to pregnant mice, just before birth until 26 termination of the progeny (22 wks old), and this did not protect NOD mice from the 27 development of T1D 169 . In a very recent study, Hanninen and colleagues reported that 28
Akkermansia muciniphila abundancy is negatively correlated to T1D development and 29 oral transfer of A. muciniphila delays diabetes development in NOD/Jax mice that, 30 otherwise, have an early disease onset 200 . However, A. muciniphila did not reduce the 31 overall incidence of diabetes 200 , whereas gavage of Clostridium butyricum 1 CGMCC0313.1 was able to significantly reduce the incidence of diabetes in NOD mice 2 by promoting regulatory T cells 201 . 3
There have been some studies investigating probiotics and host immunity in 4 humans. Treating CD children with two Bifidobacterium breve strains, Primec and co-5 authors identified changes in microbiota composition that were associated with the 6 changes in SCFAs and reduced TNFα in circulation 202 . The authors also found that 7
Verrucomicrobia, Parcibacteria and some other bacteria yet unknown phyla were 8 strongly correlated to TNFα 202 . The probiotic administration to the CD children lowered 9 the level of TNFα and reduced the abundance of Verrucomicrobia 202 . This may provide 10 potential therapeutic targets for CD. However, in a different disease setting, a reduced 11
proportion of Verrucomicrobia has also been associated with glucose intolerance in type 12 2 diabetes patients and prediabetes subjects 203 . There have also been a few studies in 13 T1D. A double-blind randomized pilot study investigated how Lactobacillus johnsonii 14 N6.2, which was shown to delay T1D onset in BB rats 198 , affects the host immunity in 15 healthy adults 204 . In this phase I human study, only healthy individuals without 16
gastrointestinal disorders or other health issues (e.g. diabetes, mental diseases, kidney and 17 heart diseases and others) were recruited for the study. The administration of L. johnsonii 18 N6.2 (taken in capsules for over 8 weeks) resulted in an increase of tryptophan in the 19 circulation 204 . It is known that tryptophan promotes Treg cell induction and expansion 20 as well as suppresses the differentiation of Th1 cells. These data suggest that L. johnsonii 21 N6.2 is safe for treatment in adults, although the authors found that the study subjects had 22 increased monocytes, NK cells and CD8 T cells in the peripheral blood compared to the 23 placebo controls 204 . It is clear that more studies need to be done before launching clinical 24 trials in the subjects with T1D or those at risk of developing T1D. 25
The Environmental Determinants of Diabetes in the Young (TEDDY) study 26 follows children at risk of developing T1D to understand how different environmental 27 factors may influence T1D susceptibility in humans. Recent data from the TEDDY study 28
have revealed a large variability in the fecal microbial probiotic (total lactobacilli and L. 29 plantarum) compositions between the children, particularly before 10 months of age 205 . 30
It is currently unknown whether those with a reduced abundance of lactobacilli in early 31 life will have a greater risk of developing T1D; however, the TEDDY study shows the 1 presence of probiotic-related bacteria in children who are at risk of developing T1D, and 2 correlating this with development of diabetes, over time, will be of considerable interest. 3 This is an ever-expanding area with more probiotic-based human T1D clinical trials 4 planned. 5 6
Fecal Microbiota Transplantation 7
Fecal microbiota transplantation (FMT) can change the gut microbiota in the 8 recipients to elicit health benefits. FMT involves processing stool from a healthy donor 9
(for allogeneic transplants) or from the recipient (autologous transplant), although more 10 often the FMT is an allogeneic transplant from a healthy donor. Sometimes the FMT 11 recipients may need to be treated with antibiotics 24-72 hours prior to FMT to eliminate 12 any existing deleterious gut microbiota. An alternative approach to fast, and have bowel 13 preparaton shortly before the treatment. FMT has been used for the treatment of severe 14
Clostridium difficile-induced colitis 206 . Many studies confirmed that FMT therapy is safe 15 and effective in treating human IBD 207 . Interestingly, FMT (from lean donor feces) 16
improves insulin sensitivity in individuals with metabolic syndrome 208 . 17
In T1D, promising results using FMT have been shown in mice. Our study 18
showed that fecal materials from MyD88 -/-NOD mice, which were protected from 19 diabetes, can delay and reduce diabetes development in NOD mouse recipients 209 20
However, there has been no report to date on whether FMT could be beneficial in Increasing evidence suggests that there are microbial perturbations in individuals 30 with islet autoimmunity or T1D compared to healthy control subjects; however, we are 31 still not clear about the defined mechanisms. Therefore, further functional studies are 1 needed, not only to probe the interaction of microbiota with immune system but also to 2 identify the causal link(s) between the presence of certain gut bacteria and diabetogenic 3 autoimmune responses. Germ-free NOD mice will provide a valuable tool in deciphering 4 the role of the microbiota in relation to the development of T1D, both in vitro, and more 5 importantly, in vivo. While GF mice are known to have a less mature immune system, 6
particularly in relation to the gut-associated mucosal lymphoid tissue 210 , GF NOD mice, 7 still develop T cell-mediated T1D 71, 138, 153, 211 . Thus, using these GF NOD mice as 8 recipients for human stool from diabetic donors and healthy control donors, allows us to 9 understand how the microbiota may modulate the immune system in T1D in vivo. 10
Studies in obesity and T2D have shown that human gut microbiota can improve glucose 11 control and insulin resistance and thus manipulation of the microbiota may also be used 12 to achieve better glycemic control in patients with T1D. 13
Diet and probiotics may provide easier acceptance and compliance in participants 14 for disease prevention and/or intervention and/or modulation of disease. However, there 15 are still some challenges e.g. in dietary interventions, the subjects have to be at the age of 16 taking solid food. As for the use of probiotics, the question remains as to how long the 17 beneficial immunomodulatory effects induced by probiotic will last and if further doses 18 are required. Moreover, while FMT may alter the gut microbiota in the longer term, 19 many of these studies pre-treat with antibiotics which provides a niche allowing newly 20 introduced microbiota to colonize. It is noteworthy that antibiotic treatment may lead to 21 antibiotic resistance. In addition, it is highly possible that FMT-induced microbiota 22 changes can be modified by diet and other factors. Therefore, for future therapy 23 development, we require further understanding of 1) microbial community interactions as 24 a complex ecosystem; 2) the interaction of host microbiome with intestinal micro-25 environment including gut epithelial cells and specialized gut endocrine cells including 26
Goblet cells and Paneth cells and 3) the interaction of gut microbiota with the host 27
immune cells locally and systemically. Furthermore, we also need to better define 28 subgroups of patients, as increasing evidence suggests that T1D is not a homogenous 29 disease condition. If we can combine the information on microbiota with clinical data, to 30 truly decipher the results by subgrouping patients based on resident microbiota 31 prevalence, c-peptide concentrations, autoantibody presence and type, as well as 1 autoreactive T cell information, we will be able to design treatment with more precision. 2
In summary, the role of microbiota in T1D is complex. While there are associations with 3 microbial composition changes at the time of seroconversion and changes associated with 4 disease onset, it remains unclear if the microbiota play a causal role in human T1D 5 development. However, studies in NOD mice have shown that microbial antigens 6 stimulated diabetogenic CD8 T cells and accelerated T1D development 103, 212 . It is clear 7 from mouse and human studies, the microbiota can induce both proinflammatory and 8
anti-inflammatory changes of the immune system. Zonulin upregulation is associated with increased gut permeability in subjects with 2 type 1 diabetes and their relatives. Diabetes 2006; 55:1443-9.  3 37. Giongo A, Gano KA, Crabb DB, Mukherjee N, Novelo LL, Casella G, et al. 4 Toward defining the autoimmune microbiome for type 1 diabetes. ISME J 2011; 
